tiprankstipranks
Trending News
More News >
TECSYS Inc. J (TSE:TCS)
TSX:TCS

TECSYS Inc. J (TCS) AI Stock Analysis

Compare
120 Followers

Top Page

TSE:TCS

TECSYS Inc. J

(TSX:TCS)

Select Model
Select Model
Select Model
Outperform 70 (OpenAI - 5.2)
,
Outperform 70 (OpenAI - 5.2)
,
Outperform 70 (OpenAI - 5.2)
Rating:70Outperform
Price Target:
C$29.00
▼(-7.11% Downside)
Action:UpgradedDate:03/06/26
Score is driven mainly by strong financial quality (rapid revenue growth, improving margins, solid cash flow, and a very low-debt balance sheet) and a constructive earnings update with reaffirmed guidance and strong bookings. The biggest offsets are an expensive valuation (high P/E) and mixed technicals with negative MACD and overbought momentum signals.
Positive Factors
SaaS ARR and bookings momentum
Sustained record bookings, rapid new-logo wins and a growing pipeline indicate durable commercial traction in enterprise healthcare distribution. This accelerates recurring ARR, diversifies customer base, and increases platform stickiness, supporting multi-quarter SaaS revenue expansion.
Conservative balance sheet and liquidity
Very low leverage and a healthy cash/short-term investment position provide financial flexibility to fund product investment, absorb execution lags, pay a dividend, or pursue strategic opportunities without refinancing risk, lowering capital structure vulnerability over months.
Improving margins and strong FCF growth
Expanding gross margins and record adjusted EBITDA coupled with rising free cash flow demonstrate improving unit economics as SaaS mix grows. Strong FCF generation supports reinvestment, shareholder returns, and resilience to cyclical downturns over a multi-quarter horizon.
Negative Factors
Low net margins and profit volatility
Despite revenue acceleration, low net margins and historical margin swings limit retained earnings and ROE improvement. Earnings volatility reduces predictability of cash flow and can constrain funding for growth initiatives unless margin gains are sustained over several quarters.
Services backlog decline
A nearly 20% decline in services backlog implies weaker near-term services revenue and slower project conversion. Since services drive implementations, slower backlog trends can delay SaaS expansions, elongate revenue recognition, and pressure cross-sell momentum across quarters.
ARR attrition and FX headwinds
Known ARR attrition and currency-driven ARR compression highlight retention and external risk to recurring revenue growth. Even modest churn and FX headwinds can materially affect ARR growth rate and forward revenue visibility in a SaaS model over the next few quarters.

TECSYS Inc. J (TCS) vs. iShares MSCI Canada ETF (EWC)

TECSYS Inc. J Business Overview & Revenue Model

Company DescriptionTecsys Inc. engages in the development, marketing, and sale of enterprise-wide supply chain management software and related services in Canada, the United States, Europe, and internationally. The company offers warehouse management, distribution and transportation management, supply management at point-of-use and order management and fulfillment, as well as financial management and analytics solutions. It also provides implementation, system enhancement, cloud, advisory, consulting, education, training, and maintenance and support services, as well as engages in sale of hardware. The company primarily serves the healthcare systems, automotive and services parts, third-party logistics, retail, and general wholesale distribution industries. Tecsys Inc. was incorporated in 1983 and is headquartered in Montreal, Canada.
How the Company Makes MoneyTECSYS primarily makes money by licensing and delivering its supply chain software and by providing services associated with deploying and maintaining that software. Key revenue streams generally include: (1) software revenue, which may include subscription/SaaS fees and/or term/perpetual license arrangements depending on customer contract structure; (2) maintenance and support, where customers pay ongoing fees for updates, product support, and continued access/support entitlements tied to the software; and (3) professional services, including implementation, configuration, integration with customer systems (e.g., ERP and automation), training, and consulting. Revenue is influenced by new customer wins, expansions within existing customers (additional modules, sites, users, or transaction volumes), renewals of recurring contracts/support, and the pace of implementation projects. Information on specific material partnerships or partner contribution levels is null.

TECSYS Inc. J Earnings Call Summary

Earnings Call Date:Mar 04, 2026
(Q3-2026)
|
% Change Since: |
Next Earnings Date:Jun 25, 2026
Earnings Call Sentiment Positive
The call communicated multiple strong operational and financial wins: record Q3 bookings, industry-leading SaaS ARR growth on a constant currency basis, record adjusted EBITDA, robust pipeline expansion (+30% YoY) and accelerating new-logo momentum (new-logo bookings +150% YoY). The commercial launch of TecsysIQ and substantial pharmacy pipeline growth (>200% YoY) position the company for continued SaaS-led growth. Near-term headwinds include known noncore customer attrition (≈CA$1M ARR effect), a CA$2.1M FX impact to sequential ARR, a 19% decline in Professional Services backlog, and a CA$4.5M one-time restructuring charge tied to a ~7% workforce reduction. On balance, the positive operational momentum, margin expansion and reaffirmed guidance materially outweigh the manageable, disclosed near-term challenges.
Q3-2026 Updates
Positive Updates
Strong SaaS Revenue and ARR Growth
SaaS revenue grew 17% year-over-year to CA$20.1M in Q3 (18% on a constant currency basis). SaaS ARR was CA$83.3M at quarter end, up 10% year-over-year (16% constant currency). Elite SaaS ARR (core product) grew 17% year-over-year (23% constant currency).
Record Adjusted EBITDA and Profitability Improvements
Adjusted EBITDA reached CA$5.0M in Q3, up 43% year-over-year and the highest adjusted EBITDA quarter in company history. Gross margin improved to 51% from 47% a year ago. Net profit was CA$1.7M (Q3 prior CA$1.2M) and EPS was CA$0.12 vs CA$0.08 a year ago. Year-to-date adjusted EBITDA increased to CA$13.3M from CA$9.1M (up ~46%).
Record Q3 SaaS Bookings and New-Logo Momentum
Company reported the largest Q3 SaaS bookings in its history, achieved without migration bookings. Bookings from new logos are up over 150% in the last 12 months versus the prior year period. Ending Q3 pipeline was up 30% year-over-year.
Strong YTD Revenue Growth and Balance Sheet Strength
For the first 9 months of FY'26, SaaS revenue was CA$58.9M (up 21% YoY), total revenue was CA$143.1M (up 10% YoY; 9% constant currency), and excluding hardware revenue grew 13% (12% CC). Cash and short-term investments were CA$36.2M and the company has no debt.
Market Traction in Healthcare and Pharmacy
Notable new logos include Memorial Sloan Kettering and UT Southwestern. Pharmacy pipeline grew more than 200% year-over-year. Pharmacy Summit registrations increased 77% YoY and participation from health system leaders rose 67% YoY, indicating strong brand and market engagement.
Commercial Launch of TecsysIQ and AI Momentum
TecsysIQ became commercially available in Q3, consolidating healthcare-specific external sources (ASHP, GUDID, FDA) with internal data to surface actionable insights. Management expects TecsysIQ to add baseline ARR (management cited ~CA$1M/yr as a baseline per year as it scales) and to act as an ARR accelerant by increasing platform stickiness.
Reaffirmed Guidance
Management reaffirmed full-year FY'26 guidance: SaaS revenue growth 20%-22%, total revenue growth 8%-10%, and adjusted EBITDA margin of 8%-9%.
Negative Updates
Known Noncore Customer Attrition and Near-Term ARR Headwind
Attrition among a small group of noncore customers (previously disclosed) will moderate reported SaaS ARR growth over the next two quarters. Management estimates roughly CA$1M of ARR headwind to play out over the next couple of quarters.
Foreign Exchange Impact on Sequential SaaS ARR
Sequential SaaS ARR increase was partially offset by an unfavorable foreign exchange impact of about CA$2.1M in the quarter.
Professional Services Backlog Decline
Professional Services backlog was CA$36M at the end of Q3, down 19% year-over-year (14% constant currency) versus a tough comp in the prior year, indicating a deceleration in services backlog compared with last year.
Workforce Reduction and One-Time Restructuring Charge
Post-quarter the company implemented a workforce reduction of approximately 7%, resulting in an estimated restructuring charge of CA$4.5M to be recorded in Q4 FY'26. Management expects this to generate approximately CA$8.1M in annual operating cost savings.
Adoption Horizon for Autonomous AI Agents
While TecsysIQ is commercially available, management cautioned that fully autonomous AI agent adoption will take additional quarters as customers build trust; widespread automated actioning is not yet broadly deployed.
Company Guidance
Management reaffirmed FY26 guidance, calling for SaaS revenue growth of 20–22%, total revenue growth of 8–10% and an adjusted EBITDA margin of 8–9%; they noted Q3 SaaS revenue was $20.1M, SaaS ARR $83.3M (Elite SaaS ARR +17% YoY, +23% constant currency), YTD SaaS revenue $58.9M (+21% YoY), and adjusted EBITDA of $5.0M in Q3 (adjusted EBITDA up 49% on an LTM basis, YTD adjusted EBITDA $13.3M vs. $9.1M prior year). They expect Q4 Professional Services revenue to look like Q3’s $15.0M (vs. last year’s Q4 $16.2M), will record an estimated $4.5M restructuring charge in Q4 tied to ~7% workforce reductions that should yield ~$8.1M in annual cost savings, have cash and short‑term investments of $36.2M with no debt, the Board approved a $0.09 quarterly dividend, and management flagged roughly $1M of known SaaS ARR attrition to play out over the next two quarters.

TECSYS Inc. J Financial Statement Overview

Summary
Strong top-line acceleration and improving operating metrics (gross margin ~50%, EBIT margin ~5%) plus solid free cash flow generation and growth. Balance sheet strength is a major positive (near-zero leverage), but net margins remain modest (~2.9%) and profitability has been historically volatile.
Income Statement
72
Positive
TTM (Trailing-Twelve-Months) revenue is up strongly (+166%), and profitability has improved versus the last annual period, with gross margin expanding to ~50% and operating profitability rising (EBIT margin ~5.0%, EBITDA margin ~7.2%). That said, net profitability remains modest (net margin ~2.9%) and is still well below earlier peak levels (e.g., materially higher margins in 2021), indicating profitability can be volatile and not yet consistently high despite the revenue acceleration.
Balance Sheet
90
Very Positive
The balance sheet is conservatively positioned with very low leverage in TTM (Trailing-Twelve-Months) debt-to-equity near zero (~0.6%) and a solid equity base (equity ~$69M on assets ~$143M). Returns have improved (TTM return on equity ~8.1%) versus recent annual levels, but are still below the company’s earlier highs, suggesting the capital structure is strong while profitability is the main driver needed to lift overall returns.
Cash Flow
76
Positive
Cash generation strengthened in TTM (Trailing-Twelve-Months), with operating cash flow ~$20.1M and free cash flow ~$13.1M, alongside very strong free cash flow growth (+53%). Free cash flow also exceeds reported earnings (free cash flow to net income ~0.58), supporting earnings quality. The main watch-out is that cash conversion from operations (as indicated by the provided coverage ratio) remains relatively low versus some prior years, implying working-capital or timing effects can create variability.
BreakdownTTMApr 2024Apr 2023Apr 2022Apr 2021Apr 2020
Income Statement
Total Revenue189.44M176.45M152.42M137.20M123.10M104.86M
Gross Profit97.05M85.29M66.81M60.31M60.63M50.32M
EBITDA13.37M11.06M7.99M10.11M15.26M8.73M
Net Income5.97M4.46M2.09M4.48M7.19M2.35M
Balance Sheet
Total Assets142.97M140.41M126.92M125.84M129.31M124.43M
Cash, Cash Equivalents and Short-Term Investments36.23M39.29M37.07M43.24M45.85M37.53M
Total Debt5.30M1.32M2.91M14.24M18.76M20.91M
Total Liabilities74.00M69.15M56.48M57.16M62.22M63.31M
Stockholders Equity68.97M71.26M70.44M68.68M67.09M61.12M
Cash Flow
Free Cash Flow13.07M11.16M5.97M2.88M17.58M8.88M
Operating Cash Flow20.07M13.91M7.76M4.94M19.11M10.01M
Investing Cash Flow-6.25M2.89M-1.11M-2.38M-13.75M-13.25M
Financing Cash Flow-10.55M-8.07M-8.42M-5.31M-7.14M15.86M

TECSYS Inc. J Technical Analysis

Technical Analysis Sentiment
Negative
Last Price31.22
Price Trends
50DMA
26.60
Negative
100DMA
30.07
Negative
200DMA
33.45
Negative
Market Momentum
MACD
0.34
Positive
RSI
46.57
Neutral
STOCH
26.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TCS, the sentiment is Negative. The current price of 31.22 is above the 20-day moving average (MA) of 26.72, above the 50-day MA of 26.60, and below the 200-day MA of 33.45, indicating a bearish trend. The MACD of 0.34 indicates Positive momentum. The RSI at 46.57 is Neutral, neither overbought nor oversold. The STOCH value of 26.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:TCS.

TECSYS Inc. J Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
C$8.57B38.3810.76%14.55%15.55%
74
Outperform
C$765.71M5.8573.40%16.25%31.71%
70
Outperform
C$387.63M55.298.57%1.07%7.00%110.62%
69
Neutral
C$3.81B49.338.24%15.11%75.40%
67
Neutral
C$869.25M14.6212.17%5.69%-0.72%-9.27%
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
59
Neutral
$7.76B12.2010.88%3.27%-5.01%13.21%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:TCS
TECSYS Inc. J
26.54
-13.33
-33.43%
TSE:OTEX
Open Text
30.95
-5.56
-15.22%
TSE:DSG
The Descartes Systems Group
99.63
-45.53
-31.37%
TSE:KXS
Kinaxis Inc
137.72
-22.12
-13.84%
TSE:ENGH
Enghouse Systems
15.95
-9.06
-36.23%
TSE:DCBO
Docebo
26.62
-16.55
-38.34%

TECSYS Inc. J Corporate Events

Business Operations and StrategyStock BuybackDividendsFinancial DisclosuresProduct-Related Announcements
Tecsys Delivers Record Q3 Results, Launches AI Platform and Cuts Jobs to Boost Efficiency
Positive
Mar 5, 2026

Tecsys reported a strong third quarter of fiscal 2026, posting record SaaS revenue of $20.1 million and record Adjusted EBITDA of $5.0 million, up 17% and 43% respectively from a year earlier. Total revenue rose to $48.5 million, net profit improved to $1.7 million, and SaaS metrics such as ARR and remaining performance obligations showed double-digit growth, underpinned by the largest Q3 bookings in the company’s history.

The quarter also saw the commercial launch of TecsysIQ, an AI intelligence layer designed to unify data and enable autonomous supply chain execution, which management says will amplify the value of its core platforms. Subsequent to quarter-end, Tecsys implemented a 7% workforce reduction expected to deliver annualized cost savings of about $8.1 million, while maintaining full-year fiscal 2026 guidance and continuing capital returns through share repurchases and a quarterly dividend of $0.09 per share.

The most recent analyst rating on (TSE:TCS) stock is a Hold with a C$28.50 price target. To see the full list of analyst forecasts on TECSYS Inc. J stock, see the TSE:TCS Stock Forecast page.

Business Operations and Strategy
Tecsys Wins Modern Healthcare Best in Business Award for Supply Chain Excellence
Positive
Jan 13, 2026

Tecsys Inc., a specialist in healthcare-focused supply chain software for functions such as pharmacy inventory management, point-of-use tracking and real-time analytics, has been named a winner in Modern Healthcare’s 2025 Best in Business Awards for supply chain excellence. The recognition underscores Tecsys’s role in shoring up supply chain resilience and visibility for major health systems, helping hospitals ensure critical products are available when and where needed and addressing industry challenges like drug shortages and fragmented demand planning, thereby strengthening its positioning as a key technology partner to leading U.S. health networks and reinforcing investor confidence in its healthcare growth strategy.

The most recent analyst rating on (TSE:TCS) stock is a Hold with a C$32.00 price target. To see the full list of analyst forecasts on TECSYS Inc. J stock, see the TSE:TCS Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 06, 2026